Research ArticleOriginal Research

Comparing Cannabis Use for Pain to Use for Other Reasons in Primary Care Patients

Morgan A. Ford, Gwen T. Lapham, Theresa E. Matson, Casey Luce, Malia M. Oliver and Ingrid A. Binswanger
The Journal of the American Board of Family Medicine November 2023, 36 (6) 996-1007; DOI: https://doi.org/10.3122/jabfm.2023.230163R1

References

  1. 1.↵
    1. Azcarate PM,
    2. Zhang AJ,
    3. Keyhani S,
    4. Steigerwald S,
    5. Ishida JH,
    6. Cohen BE
    . Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US population. J Gen Intern Med 2020;35:1979–86.
    OpenUrl
  2. 2.↵
    Colorado Department of Public Health and Environment. Medical marijuana statistics and data. 2022. Available at: https://cdphe.colorado.gov/medical-marijuana-registry-data.
  3. 3.↵
    1. Ilgen MA,
    2. Bohnert K,
    3. Kleinberg F,
    4. et al
    . Characteristics of adults seeking medical marijuana certification. Drug Alcohol Depend 2013;132:654–9.
    OpenUrlPubMed
  4. 4.↵
    1. Kosiba JD,
    2. Maisto SA,
    3. Ditre JW
    . Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis. Soc Sci Med 2019;233:181–92.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Leung J,
    2. Chan G,
    3. Stjepanovic D,
    4. Chung JYC,
    5. Hall W,
    6. Hammond D
    . Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology (Berl) 2022;239:1509–19.
    OpenUrl
  6. 6.↵
    1. Sexton M,
    2. Cuttler C,
    3. Finnell JS,
    4. Mischley LK
    . A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res 2016;1:131–8.
    OpenUrl
  7. 7.↵
    1. Yang KH,
    2. Kaufmann CN,
    3. Nafsu R,
    4. et al
    . Cannabis: an emerging treatment for common symptoms in older adults. J Am Geriatr Soc 2021;69:91–7.
    OpenUrlCrossRef
  8. 8.↵
    1. Mucke M,
    2. Phillips T,
    3. Radbruch L,
    4. Petzke F,
    5. Hauser W
    . Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2018;3:CD012182.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Stockings E,
    2. Campbell G,
    3. Hall WD,
    4. et al
    . Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 2018;159:1932–54.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Wang L,
    2. Hong PJ,
    3. May C,
    4. et al
    . Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ 2021;374:n1034.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Klieger SB,
    2. Gutman A,
    3. Allen L,
    4. et al
    . Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Addiction 2017;112:2206–16.
    OpenUrl
  12. 12.↵
    1. Tetrault JM,
    2. Crothers K,
    3. Moore BA,
    4. et al
    . Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007;167:221–8.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Tashkin DP
    . Marijuana and lung disease. Chest 2018;154:653–63.
    OpenUrlPubMed
  14. 14.↵
    1. Tan WC,
    2. Bourbeau J,
    3. Aaron SD
    , Members of the CanCOLD Collaborative Research Group not listed as authorset al. The effects of marijuana smoking on lung function in older people. Eur Respir J 2019;54.
  15. 15.↵
    National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017.
  16. 16.↵
    1. Ghasemiesfe M,
    2. Ravi D,
    3. Vali M,
    4. et al
    . Marijuana use, respiratory symptoms, and pulmonary function: a systematic review and meta-analysis. Ann Intern Med 2018;169:106–15.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Heinzerling A,
    2. Armatas C,
    3. Karmarkar E,
    4. et al
    . Severe lung injury associated with use of e-cigarette, or vaping, products-California, 2019. JAMA Intern Med 2020;180:861–9.
    OpenUrl
  18. 18.↵
    1. Cherian SV,
    2. Kumar A,
    3. Estrada YMRM
    . E-cigarette or vaping product-associated lung injury: a review. Am J Med 2020;133:657–63.
    OpenUrlPubMed
  19. 19.↵
    1. Chesney E,
    2. McGuire P,
    3. Freeman TP,
    4. Strang J,
    5. Englund A
    . Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products. Ther Adv Psychopharmacol 2020;10:2045125320954992.
    OpenUrl
  20. 20.↵
    1. Sorkhou M,
    2. Bedder RH,
    3. George TP
    . The behavioral sequelae of cannabis use in healthy people: a systematic review. Front Psychiatry 2021;12:630247.
    OpenUrl
  21. 21.↵
    1. Robinson T,
    2. Ali MU,
    3. Easterbrook B,
    4. et al
    . Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. Psychol Med 2022;53:1–11.
    OpenUrlPubMed
  22. 22.↵
    1. Ortiz-Medina MB,
    2. Perea M,
    3. Torales J,
    4. et al
    . Cannabis consumption and psychosis or schizophrenia development. Int J Soc Psychiatry 2018;64:690–704.
    OpenUrlPubMed
  23. 23.↵
    1. Escelsior A,
    2. Belvederi Murri M,
    3. Corsini GP,
    4. et al
    . Cannabinoid use and self-injurious behaviours: a systematic review and meta-analysis. J Affect Disord 2021;278:85–98.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Robinson T,
    2. Ali MU,
    3. Easterbrook B,
    4. et al
    . Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: a systematic review and meta-analysis. Drug Alcohol Depend 2022;238:109582.
    OpenUrl
  25. 25.↵
    Substance Abuse and Mental Health Services Administration. 2021 NSDUH: state-specific tables. 2023. Available at: https://www.samhsa.gov/data/report/2021-nsduh-detailed-tables.
  26. 26.↵
    National Conference of State Legislatures. State medical cannabis laws 2022 [updated July 18, 2022. Available at: https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.
  27. 27.↵
    1. Lapham GT,
    2. Matson TE,
    3. Carrell DS,
    4. et al
    . Comparison of medical cannabis use reported on a confidential survey vs documented in the electronic health record among primary care patients. JAMA Netw Open 2022;5:e2211677.
    OpenUrl
  28. 28.↵
    1. Matson TE,
    2. Lapham GT,
    3. Bobb JF,
    4. et al
    . Validity of the single-item screen-cannabis (SIS-C) for cannabis use disorder screening in routine care. JAMA Netw Open 2022;5:e2239772.
    OpenUrl
  29. 29.↵
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Ed.: American Psychiatric Publishing; 2013.
  30. 30.↵
    Centers for Disease Control and Prevention. Behavioral risk factor surveillance system. annual survey data. 2021. Available at: https://www.cdc.gov/brfss/annual_data/annual_data.htm.
  31. 31.↵
    1. Lapham G,
    2. Boudreau DM,
    3. Johnson EA
    , PROUD Collaborative Investigatorset al. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug Alcohol Depend 2020;207:107732.
    OpenUrl
  32. 32.↵
    1. Mayhew M,
    2. DeBar LL,
    3. Deyo RA,
    4. et al
    . Development and assessment of a crosswalk between ICD-9-CM and ICD-10-CM to identify patients with common pain conditions. J Pain 2019;20:1429–45.
    OpenUrlPubMed
  33. 33.↵
    1. Zou G
    . A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702–6.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Greenland S
    . Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology 1995;6:450–4.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Dowell D,
    2. Ragan KR,
    3. Jones CM,
    4. Baldwin GT,
    5. Chou R
    . CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep 2022;71:1–95.
    OpenUrl
  36. 36.↵
    1. Zelaya CE,
    2. Dahlhamer JM,
    3. Lucas JW,
    4. Connor EM
    . Chronic pain and high-impact chronic pain among U.S. adults. NCHS Data Brief 2019;2020:1–8.
    OpenUrl
  37. 37.↵
    1. Mills SEE,
    2. Nicolson KP,
    3. Smith BH
    . Chronic pain: a review of its epidemiology and associated factors in population-based studies. Br J Anaesth 2019;123:e273–e83.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Zvolensky MJ,
    2. McMillan K,
    3. Gonzalez A,
    4. Asmundson GJ
    . Chronic pain and cigarette smoking and nicotine dependence among a representative sample of adults. Nicotine Tob Res 2009;11:1407–14.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Ditre JW,
    2. Brandon TH,
    3. Zale EL,
    4. Meagher MM
    . Pain, nicotine, and smoking: research findings and mechanistic considerations. Psychol Bull 2011;137:1065–93.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Ditre JW,
    2. Heckman BW,
    3. Zale EL,
    4. Kosiba JD,
    5. Maisto SA
    . Acute analgesic effects of nicotine and tobacco in humans: a meta-analysis. Pain 2016;157:1373–81.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Wershoven N,
    2. Kennedy AG,
    3. MacLean CD
    . Use and reported helpfulness of cannabinoids among primary care patients in Vermont. J Prim Care Community Health 2020;11:2150132720946954.
    OpenUrl
  42. 42.↵
    1. AminiLari M,
    2. Kithulegoda N,
    3. Strachan P,
    4. et al
    . Benefits and concerns regarding use of cannabis for therapeutic purposes among people living with chronic pain: a qualitative research study. Pain Med 2022.
  43. 43.↵
    1. Guo Y,
    2. Kopec JA,
    3. Cibere J,
    4. Li LC,
    5. Goldsmith CH
    . Population survey features and response rates: a randomized experiment. Am J Public Health 2016;106:1422–6.
    OpenUrlPubMed
  44. 44.↵
    1. Lallukka T,
    2. Pietilainen O,
    3. Jappinen S,
    4. et al
    . Factors associated with health survey response among young employees: a register-based study using online, mailed and telephone interview data collection methods. BMC Public Health 2020;20:184.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords